SuperworthBristol-Myers Squibb EPS BMY
Diluted earnings per share by quarter and over the last twelve months, from 2008.
- Last 12 months, to Jun 30, 2026
- $4.54
- Latest quarter, Q2 FY26
- $1.62
- +153% on a year earlier
- Fiscal year 2025
- $3.45
Bristol-Myers Squibb's earnings per share was $4.54 over the twelve months to Jun 30, 2026, up 83% on a year earlier.
In its latest quarter, Q2 FY26, it was $1.62, up 153% on the same quarter a year before.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | $3.45 | n/a |
| FY2024 | −$4.42 | −215% |
| FY2023 | $3.86 | +31% |
| FY2022 | $2.95 | −5% |
| FY2021 | $3.12 | n/a |
| FY2020 | −$4.01 | −283% |
| FY2019 | $2.19 | −27% |
| FY2018 | $3.01 | +410% |
| FY2017 | $0.59 | −78% |
| FY2016 | $2.65 | +185% |
| FY2015 | $0.93 | −23% |
| FY2014 | $1.20 | −23% |
| FY2013 | $1.55 | +35% |
| FY2012 | $1.15 | −47% |
| FY2011 | $2.15 | +20% |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $1.62 | +153% | $4.54 | |
| Q1 FY26 | $1.31 | +9% | $3.56 | |
| Q4 FY25 | $0.53 | +1225% | $3.45 | |
| Q3 FY25 | $1.08 | +80% | $2.96 | |
| Q2 FY25 | $0.64 | −23% | $2.48 | |
| Q1 FY25 | $1.20 | n/a | $2.67 | |
| Q4 FY24 | $0.04 | −95% | −$4.42 | |
| Q3 FY24 | $0.60 | −35% | −$3.59 | |
| Q2 FY24 | $0.83 | −16% | −$3.26 | |
| Q1 FY24 | −$5.89 | −650% | −$3.10 | |
| Q4 FY23 | $0.87 | −8% | $3.86 | |
| Q3 FY23 | $0.93 | +24% | $3.94 |
Against its peers
Companies in Drug Manufacturers - General nearest Bristol-Myers Squibb's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| BMYBristol-Myers Squibb | $4.54 | +83% a year |
| PFEPfizer | $0.76 | −60% a year |
| GILDGilead Sciences | −$2.67 | −153% a year |
| AMGNAmgen | $16.09 | +32% a year |
| MRKMerck | $1.25 | −81% a year |
| BIIBBiogen | $5.65 | −46% a year |
| ABBVAbbVie | $3.54 | +69% a year |
| JNJJohnson & Johnson | $6.60 | −36% a year |
| JAZZJazz Pharmaceuticals | $14.62 | |
| LLYEli Lilly and | $29.80 | +95% a year |
| Peer median | $5.65 |
Where Bristol-Myers Squibb ranks
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Bristol-Myers Squibb
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.